Published in J Clin Invest on October 01, 1993
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci U S A (2007) 1.87
Thrombin. Mol Aspects Med (2008) 1.80
Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model. Thromb Haemost (2012) 1.42
Science review: role of coagulation protease cascades in sepsis. Crit Care (2002) 1.37
New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care (2005) 1.24
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin. Blood (2010) 1.01
Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesth (2009) 0.96
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke (2011) 0.94
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. Crit Care (2011) 0.89
Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest (1997) 0.83
Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates. Sci Transl Med (2010) 0.81
Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Blood Cells Mol Dis (2013) 0.81
Immobilization of actively thromboresistant assemblies on sterile blood-contacting surfaces. Adv Healthc Mater (2013) 0.80
A biologically active surface enzyme assembly that attenuates thrombus formation. Adv Funct Mater (2011) 0.79
Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits. J Clin Invest (1995) 0.78
Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation. J Thromb Thrombolysis (2013) 0.76
Human activated protein C variants in a rat model of arterial thrombosis. Thromb J (2008) 0.75
Rational Design of Protein C Activators. Sci Rep (2017) 0.75
Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. Int J Cardiol (2016) 0.75
Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale. Eplasty (2015) 0.75
Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A (1981) 3.88
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood (1990) 3.38
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry (1977) 2.96
Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry (1980) 2.89
The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta (1979) 2.83
Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med (1984) 2.26
Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest (1979) 2.18
Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem (1981) 1.94
Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science (1990) 1.75
Alterations in blood coagulation mechanism after intra-aortic injection of thrombin. Arch Surg (1960) 1.65
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood (1982) 1.58
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet (1983) 1.53
Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation (1990) 1.52
Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. J Clin Invest (1980) 1.51
Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest (1981) 1.50
Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation (1991) 1.50
Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation (1991) 1.47
Thrombin-cellular interactions. Ann N Y Acad Sci (1986) 1.47
Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci U S A (1991) 1.35
Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A (1988) 1.34
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood (1985) 1.33
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A (1985) 1.27
The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood (1989) 1.26
A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med (1987) 1.25
Activation of protein C in vivo. J Clin Invest (1982) 1.20
Direct detection of activated protein C in blood from human subjects. Blood (1992) 1.17
Fibrin polymerization and its regulatory role in hemostasis. J Lab Clin Med (1990) 1.11
Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood (1989) 1.08
Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest (1988) 1.03
Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis (1985) 0.99
Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem (1987) 0.95
A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol (1988) 0.94
Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest (1984) 0.93
Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost (1990) 0.91
The relation of platelet density to platelet age: survival of low- and high-density 111indium-labeled platelets in baboons. Blood (1986) 0.90
Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood (1991) 0.90
The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem (1993) 0.88
Prevention of acquired transient defect in platelet plug formation by infused prostacyclin. Blood (1981) 0.88
Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. J Lab Clin Med (1989) 0.87
Thrombin and acetylated thrombin in the activation of fibrinolysis. Can J Physiol Pharmacol (1968) 0.85
Effects of red blood cell concentration on hemostasis and thrombus formation in a primate model. Blood (1990) 0.83
RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. J Clin Invest (1989) 0.82
Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. J Clin Invest (1984) 0.82
Baboon models of acute arterial thrombosis. Thromb Haemost (1987) 0.81
Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. Thromb Res (1991) 0.81
Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol (1990) 0.81
In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood (1991) 0.80
Functional assays for protein C activity and protein C inhibitor activity in plasma. Thromb Haemost (1989) 0.79
A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood (1990) 0.79
Thromboembolic potential of synthetic vascular grafts in baboons. J Vasc Surg (1989) 0.78
The kinetics of baboon fibrinogen adsorption to polymers: in vitro and in vivo studies. J Biomed Mater Res (1986) 0.78
Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res (1986) 0.77
Hemorrhagic syndrome in dogs induced by intravenous thrombin. Thromb Diath Haemorrh (1966) 0.76
The genome sequence of the plant pathogen Xylella fastidiosa. The Xylella fastidiosa Consortium of the Organization for Nucleotide Sequencing and Analysis. Nature (2000) 10.03
Comparison of the genomes of two Xanthomonas pathogens with differing host specificities. Nature (2002) 8.42
Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet (1995) 5.07
Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med (2001) 4.10
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A (1981) 3.88
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem (1982) 3.51
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest (1976) 3.04
Intra-aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow-diversion treatment. AJNR Am J Neuroradiol (2010) 3.03
Factors influencing endothelial cell proliferation in vitro. J Cell Physiol (1978) 2.99
Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. Proc Natl Acad Sci U S A (1999) 2.87
The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta (1979) 2.83
Thrombogenesis in sickle cell disease. J Lab Clin Med (2001) 2.75
The bleeding time as a screening test for evaluation of platelet function. N Engl J Med (1972) 2.73
The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome. Proc Natl Acad Sci U S A (2001) 2.71
Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost (2005) 2.70
The regulation of natural anticoagulant pathways. Science (1987) 2.58
The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A (1996) 2.58
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med (1974) 2.55
Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem (1994) 2.52
Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost (2011) 2.51
Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest (1981) 2.50
Observation of coherent oscillations in a single electron spin. Phys Rev Lett (2004) 2.44
Bleeding complications associated with cardiopulmonary bypass. Blood (1990) 2.43
Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A (1986) 2.43
Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A (2001) 2.33
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem (1979) 2.21
Platelet and fibrinogen consumption in man. N Engl J Med (1972) 2.20
The conversion of prothrombin to thrombin. I. Characterization of the reaction products formed during the activation of bovine prothrombin. J Biol Chem (1974) 2.19
The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem (1991) 2.14
Observation of coherent oscillation of a single nuclear spin and realization of a two-qubit conditional quantum gate. Phys Rev Lett (2004) 2.12
Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest (1983) 2.08
Ferrokinetics in man. Medicine (Baltimore) (1970) 2.08
Gross and microscopic histopathological findings in aneurysms of the human brain treated with Guglielmi detachable coils. J Neurosurg (1999) 2.06
The interaction of a Ca2+-dependent monoclonal antibody with the protein C activation peptide region. Evidence for obligatory Ca2+ binding to both antigen and antibody. J Biol Chem (1988) 2.06
Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem (1982) 2.04
Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest (1980) 2.01
Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med (1970) 1.99
Thrombokinetics in man. J Clin Invest (1969) 1.99
Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med (1984) 1.98
Glutathione redox cycle protects cultured endothelial cells against lysis by extracellularly generated hydrogen peroxide. J Clin Invest (1984) 1.94
Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem (1981) 1.94
The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood (1980) 1.91
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Effective and efficient platelet transfusion strategies that maintain hemostatic protection. Transfusion (1998) 1.86
Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags. Proc Natl Acad Sci U S A (2000) 1.84
Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest (1984) 1.84
Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 1.82
Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation (1997) 1.81
The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood (2000) 1.80
Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem (1994) 1.77
Proteolytic formation and properties of gamma-carboxyglutamic acid-domainless protein C. J Biol Chem (1983) 1.77
Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest (1987) 1.74
Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost (2007) 1.73
Exaggerated platelet reactivity in major depression. Am J Psychiatry (1996) 1.72
Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem (1979) 1.72
Neutrophil kinetics in man. J Clin Invest (1976) 1.72
A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO3- into prothrombin. J Biol Chem (1975) 1.71
American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med (2001) 1.70
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation (2001) 1.67
A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost (2003) 1.67
A polypeptide region of bovine prothrombin specific for binding to phospholipids. Proc Natl Acad Sci U S A (1973) 1.65
Experimental acute thrombotic stroke in baboons. Stroke (1987) 1.64
A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem (1976) 1.64
Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood (1989) 1.64
Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res (1980) 1.63
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem (1989) 1.63
Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest (1980) 1.61
Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost (1991) 1.59
Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem (1990) 1.59
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A (1976) 1.59
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood (1982) 1.58
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury. Thorax (2008) 1.58
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Serum vitamin B12 levels and incidence of dementia in a healthy elderly population: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc (1994) 1.57
The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem (1996) 1.56
The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest (1977) 1.55
Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem (2000) 1.54
Vitamin K-dependent carboxylase. Requirements of the rat liver microsomal enzyme system. J Biol Chem (1976) 1.53
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet (1983) 1.53
Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest (1980) 1.53
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood (1984) 1.52
Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation (1990) 1.52
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res (2000) 1.52
Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood (2001) 1.51
Activated protein C inhibits platelet prothrombin-converting activity. Blood (1979) 1.51
Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem (1993) 1.51
The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem (1992) 1.50
Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation (1991) 1.50
Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest (1981) 1.50
Molecular karyotype of clone CL Brener chosen for the Trypanosoma cruzi genome project. Mol Biochem Parasitol (1995) 1.48
Interpretation of electrocochleography in Menière's disease and normal subjects. Ann Otol Rhinol Laryngol (1992) 1.48